Novo Nordisk has begun phase III trial with antibody
Last summer, Novo Nordisk acquired the US-based biotech company Corvidia Therapeutics to access the antibody ziltivekimab. The pharmaceutical company has now commenced a phase III study of the drug, the company confirms in comment to MedWatch.
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY DANIEL PEDERSEN
In the beginning of September, Novo Nordisk started a phase III with the antibody ziltivekimab, which the company received in a million-dollar acquisition of the US-based company Corvidia Therapeutics last year, according to database Clinicaltrials.gov, which collects information about clinical studies, and Novo Nordisk confirms as much in comment to MedWatch.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk creates new RNA and gene therapy unit
For subscribers
.jpg)
.jpg&w=384&q=75)
